{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:17:50Z","timestamp":1781014670655,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T00:00:00Z","timestamp":1358553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T00:00:00Z","timestamp":1358553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s40273-012-0020-7","type":"journal-article","created":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T09:05:13Z","timestamp":1358499913000},"page":"125-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination"],"prefix":"10.1007","volume":"31","author":[{"given":"Thomas D.","family":"Szucs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena M.","family":"Pfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,19]]},"reference":[{"issue":"4","key":"20_CR1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1155\/2009\/380384","volume":"14","author":"GJ Bennett","year":"2009","unstructured":"Bennett GJ, Watson CPN. Herpes zoster and post-herpetic neuralgia: past, present, and future. Pain Res Manage. 2009;14(4):275\u201382.","journal-title":"Pain Res Manage"},{"issue":"5","key":"20_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7326\/0003-4819-154-5-201103010-01003","volume":"154","author":"JF Wilson","year":"2011","unstructured":"Wilson JF. Herpes zoster. Ann Intern Med. 2011;154(5):3\u201315.","journal-title":"Ann Intern Med"},{"issue":"10","key":"20_CR3","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ejpain.2011.04.014","volume":"15","author":"A Benbernou","year":"2011","unstructured":"Benbernou A, Drolet M, Levin MJ, et al. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain. 2011;15(10):1100\u20136.","journal-title":"Eur J Pain"},{"issue":"1","key":"20_CR4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1155\/2010\/178036","volume":"21","author":"G Boivin","year":"2010","unstructured":"Boivin G, Jovey R, Elliott CT, et al. Management and prevention of herpes zoster: a Canadian perspective. Can J Infect Dis Med Microbiol. 2010;21(1):45\u201352.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"8","key":"20_CR5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/AJP.0b013e3181eef686","volume":"26","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Levin MF, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656\u201366.","journal-title":"Clin J Pain"},{"issue":"50","key":"20_CR6","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.1016\/j.vaccine.2010.09.074","volume":"28","author":"SG Chiappe","year":"2010","unstructured":"Chiappe SG, Sarazin M, Turbelin C, et al. Herpes zoster: burden of disease in France. Vaccine. 2010;28(50):7933\u20138.","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"20_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S1386-6532(10)70002-0","volume":"48","author":"AA Gershon","year":"2010","unstructured":"Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48(Suppl. 1):2\u20137.","journal-title":"J Clin Virol"},{"key":"20_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1471-2334-10-230","volume":"10","author":"LE Gialloreti","year":"2010","unstructured":"Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.","journal-title":"BMC Infect Dis"},{"key":"20_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/1471-2334-11-173","volume":"11","author":"B Ultsch","year":"2011","unstructured":"Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.","journal-title":"BMC Infect Dis"},{"issue":"Suppl. 2","key":"20_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1086\/522153","volume":"197","author":"LP Hurley","year":"2008","unstructured":"Hurley LP, Harpaz R, Daley MF, et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis. 2008;197(Suppl. 2):216\u201323.","journal-title":"J Infect Dis"},{"issue":"2","key":"20_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amepre.2010.10.012","volume":"40","author":"P Lu","year":"2011","unstructured":"Lu P, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):1\u20136.","journal-title":"Am J Prev Med"},{"issue":"2","key":"20_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1001\/jama.2010.1983","volume":"305","author":"HF Tseng","year":"2011","unstructured":"Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160\u20136.","journal-title":"JAMA"},{"issue":"6","key":"20_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s15010-011-0162-0","volume":"39","author":"A Hata","year":"2011","unstructured":"Hata A, Kuniyoshi M, Ohkusa Y. Risk of herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39(6):537\u201344.","journal-title":"Infection"},{"issue":"2\u20133","key":"20_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0304-3959(96)03122-3","volume":"67","author":"RH Dworkin","year":"1996","unstructured":"Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996;67(2\u20133):241\u201351.","journal-title":"Pain"},{"issue":"6","key":"20_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/AJP.0b013e318065b6c9","volume":"23","author":"KE Schmader","year":"2007","unstructured":"Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23(6):490\u20136.","journal-title":"Clin J Pain"},{"issue":"16","key":"20_CR16","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1503\/cmaj.091711","volume":"182","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182(16):1731\u20136.","journal-title":"CMAJ"},{"issue":"6","key":"20_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.respe.2010.06.166","volume":"58","author":"G Mick","year":"2010","unstructured":"Mick G, Gallais JL, Simon F, et al. Burden of herpes zoster and post-herpetic neuralgia: incidence, proportion, and associated costs in the French population aged 50 or over [in French]. Rev Epidemiol Sante Publique. 2010;58(6):393\u2013401.","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"1","key":"20_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00019053-200321010-00002","volume":"21","author":"N Thiry","year":"2003","unstructured":"Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics. 2003;21(1):13\u201338.","journal-title":"Pharmacoeconomics"},{"key":"20_CR19","unstructured":"Centers for Disease Control and Prevention. Childhood immunization schedule, 2011. Atlanta: CDC; 2011. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6005a6.htm. Accessed 1 Sept 2011."},{"key":"20_CR20","unstructured":"Centers for Disease Control and Prevention. Adult immunization schedule, 2011. Atlanta: CDC. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6004a10.htm. Accessed 1 Sept 2011."},{"issue":"2","key":"20_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/10489140-000000000-00000","volume":"27","author":"M Sanford","year":"2010","unstructured":"Sanford M, Keating GM. Zoster vaccine (Zostavax\u00ae): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27(2):159\u201376.","journal-title":"Drugs Aging"},{"issue":"22","key":"20_CR22","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271\u201384.","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"20_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S1386-6532(10)70004-4","volume":"48","author":"MJ Levin","year":"2010","unstructured":"Levin MJ, Gershon AA, Dworkin RH, et al. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol. 2010;48(Suppl. 1):14\u20139.","journal-title":"J Clin Virol"},{"issue":"Suppl. 2","key":"20_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1086\/522159","volume":"197","author":"MN Oxman","year":"2008","unstructured":"Oxman MN, Levin MJ, et al. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008;197(Suppl. 2):228\u201336.","journal-title":"J Infect Dis"},{"key":"20_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275\u201383.","journal-title":"BMJ"},{"issue":"1","key":"20_CR26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.18553\/jmcp.2003.9.1.53","volume":"9","author":"JJ Ofman","year":"2003","unstructured":"Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53\u201361.","journal-title":"J Manag Care Pharm"},{"issue":"23\u201324","key":"20_CR27","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1016\/S0264-410X(01)00044-5","volume":"19","author":"WJ Edmunds","year":"2001","unstructured":"Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23\u201324):3076\u201390.","journal-title":"Vaccine"},{"issue":"5","key":"20_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/0003-4819-145-5-200609050-00004","volume":"145","author":"J Hornberger","year":"2006","unstructured":"Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145(5):317\u201325.","journal-title":"Ann Intern Med"},{"issue":"49","key":"20_CR29","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","volume":"25","author":"JM Pellissier","year":"2007","unstructured":"Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25(49):8326\u201337.","journal-title":"Vaccine"},{"issue":"10","key":"20_CR30","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1086\/514342","volume":"44","author":"MB Rothberg","year":"2007","unstructured":"Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280\u20138.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"20_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4161\/hv.4.3.5686","volume":"4","author":"M Brisson","year":"2008","unstructured":"Brisson M, Pellissier JM, Camden S, et al. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008;4(3):238\u201345.","journal-title":"Hum Vaccin"},{"issue":"12","key":"20_CR32","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2165\/11314010-000000000-00000","volume":"27","author":"M Najafzadeh","year":"2009","unstructured":"Najafzadeh M, Marra CA, Galanis E, et al. Cost-effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27(12):991\u20131004.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"20_CR33","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","volume":"27","author":"AJ van Hoek","year":"2009","unstructured":"van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454\u201367.","journal-title":"Vaccine"},{"issue":"3","key":"20_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3111\/13696998.2010.502854","volume":"13","author":"L Annemans","year":"2010","unstructured":"Annemans L, Bresse X, Gobbo C, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537\u201351.","journal-title":"J Med Econ"},{"key":"20_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1478-7547-8-7","volume":"8","author":"L Moore","year":"2010","unstructured":"Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010;8:7.","journal-title":"Cost Eff Resour Alloc"},{"key":"20_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/1472-6963-10-237","volume":"10","author":"A van Lier","year":"2010","unstructured":"van Lier A, van Hoek AJ, Opstelten W, et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.","journal-title":"BMC Health Serv Res"},{"key":"20_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(06)68032-X","volume":"367","author":"AJ van Wijck","year":"2006","unstructured":"van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet. 2006;367:219\u201324.","journal-title":"Lancet"},{"issue":"7","key":"20_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.4161\/hv.7.7.15573","volume":"7","author":"TD Szucs","year":"2011","unstructured":"Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7(7):749\u201356.","journal-title":"Hum Vaccin"},{"key":"20_CR39","unstructured":"Michel JP, Kempf W. Data collection related to the management of herpes zoster (HZ) and post-herpetic neuralgia (PHN) and demographic parameters in Switzerland 2007 [unpublished]."},{"issue":"7","key":"20_CR40","doi-asserted-by":"publisher","first-page":"A294","DOI":"10.1016\/S1098-3015(10)74442-9","volume":"12","author":"J Wasem","year":"2009","unstructured":"Wasem J, Lang K, Papageorgiou M, et al. Health economic evaluation of a new vaccine for the prevention of herpes zoster and post-herpetic neuralgia in adults a German analysis [abstract no. PIH22]. Value Health. 2009;12(7):A294.","journal-title":"Value Health"},{"issue":"6 Suppl.","key":"20_CR41","doi-asserted-by":"publisher","first-page":"145S","DOI":"10.1097\/MLR.0b013e3181d9913b","volume":"48","author":"PA Ollendorf","year":"2010","unstructured":"Ollendorf PA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. Med Care. 2010;48(6 Suppl.):145S\u201352S.","journal-title":"Med Care"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-012-0020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-012-0020-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-012-0020-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-012-0020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:30:12Z","timestamp":1659112212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-012-0020-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,19]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["20"],"URL":"https:\/\/doi.org\/10.1007\/s40273-012-0020-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,19]]},"assertion":[{"value":"19 January 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}